Business
OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
— PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024 — Expansion of PI3Ka franchise to include a pan-mutant selective program; development candidate expected to be announced in Q2 2025 — $111M in cash and cash equivalents expected to be sufficient to fund operations through multiple PIKture-01 clinical readouts and anticipated milestones into Q4 2026 BOU
About this update from Onkure Therapeutics, Inc.
[{"type":"image","alt":"OnKure Therapeutics, Inc.","displaySize":"","headline":null,"caption":"OnKure Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/80a75f50988a3e7732dc404944bce001"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lmQIfegLNApEkytHgGTsoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/80a75f50988a3e7732dc404944bce001","width":300,"height":150}},"lazy":false},{"type":"text","content":"— PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024","length":196,"tagName":"p"},{"type":"text","content":"— Expansion of PI3Ka franchise to include a pan-mutant selective program; development candidate expected to be announced in Q2 2025","length":131,"tagName":"p"},{"type":"text","content":"— $111M in cash and cash equivalents expected to be sufficient to fund operations through multiple PIKture-01 clinical readouts and anticipated milestones into Q4 2026","length":167,"tagName":"p"},{"type":"text","content":"BOULDER, Colo., March 10, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines in oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business highlights.","length":332,"tagName":"p"},{"type":"text","content":"“I am extremely pleased with the progress we made last year. With three PI3Ka inhibitor programs, including one in clinical development and a second development candidate expected next quarter, we are committed to developing product candidates that address the needs of patients who suffer from diseases implicated by PI3Ka, which is a key mediator in cancer growth signaling,” said Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure.","length":458,"tagName":"p"},{"type":"text","content":"“The extensive expertise of our research and development team in discovering development candidates with favorable drug properties is our strength, and the entire OnKure team is contributing to the execution of our strategy. This year, we expect to report addition...